Progesterone and the prolonged progestational state: co-carcinogenic factors in mammary tumor induction. by Poel, W. E.
824
PROGESTERONE AND THE PROLONGED PROGESTATIONAL
STATE: CO-CARCINOGENIC FACTORS IN MAMMARY
TUMOR INDUCTION
W. E. POEL
From the Gradiuate School of Public Health. University of Pittsburyh. Pittsburgh
Pennsyli'ania. U.S.A.
Receive(d for p)u1)lieation September 3. 1963,
The physiologic basis for the current form of oral contraception is induction of
a persistent anovulatory and uterine state that characterized progestation. by
daily ingestion ofsynthetic progestins. The practice is sufficiently popular among
women in many countries to insure adequate epidemiologic data within the near
future on any pathologic consequences related to it. To date. relatively few
studies of humans or laboratory animals have been published to show the long-
term biological effects of the agents ingested, or of persistent disruption in normal
hormonal cycles by the prolonged progestational periods so induced (Tyler, 1]964).
A small but impressive body ofliterature does indicate direct relationships between
mammary carcinogenesis in laboratory animals and the hormones ofprogestation,
e.g., the enhancement ofmanmmary carcinogenesis in rats treated with a carcinogen
and exogenous progesterone (Cantarow, Stasney and Paschkis, 1948: Huggins.
Briziarelli and Sutton, 1959), and in mice treated with a carcinogen and estrogen,
or estrogen and progesterone (Gardner, Pfeiffer, and Trentin, 1959: Jull. 1954:
Sydnor and Cockrell, 1963). The facts that many recognized carcinogens affect
man in his every-day environment, and that the etiology of mammary cancer in
the human is still unknown provide a practical rationale for studying the joint
effects of known carcinogens and progestins in experimental animals. The study
now reported describes the effects of a prolonged progestational state. induced bv
repeated injections of progesterone. on the development of mammary cancers in
intact mice 1predisposed to those neoplasms.
MATERIALS AND METHO DS
C31H iJax mice. bought from the Jackson Laboratory. Bar Harbor, Maine.
(arry a virus, the mammary tumor agent (MTA),. which has induced mammary
adenocarcinoma in from 1.40/ of untreated virgin females 26 weeks of age to
1060o, 39 weeks of age, respectively (Murray. 1965). For this experiment, 125
C3H females 9 to 10 weeks of age on initial exposure were housed in plastic cages,
5 mice to a cage. in which they had free access to tap water and Purina chow.
Five cages containing 25 mice, chosen at random, were assigned to each of 5
different exposure groups (Table I, columns 1 and 2).
Treatments for Group I consisted of:
(a) Five subcutaneous injections per week, delivered daily, alternately
in the region of the right and left inguinal lymph nodes, of 0 05 ml. of 5%
progesteroine in peanut oil, for a total of 19 weeks; andPROGESTERONE AND MAMMARY TUMORS
(b) tmo forced feedings per week of 0 1 ml. of a carciinogenic solutioni
c*ontaining 0.500 3-methylcholanthrene (MCA) in Tween-60, passed
directly into the forestomach by means of a gastric tube (Poel. 1963).
T'reatments " b " were begun 2 weeks after " a " and were continued until grossly
palpable tumors with diameters greater than 6 mm. were detected.
Treatments for Group II consisted of: a(C) subcutaneous " control " injections
of peanut oil, concurrently and quantitatively equivalent to those of " a " for
Group I; and (b) MCA feedings concurrently and quantitatively equivalent to
b " for Grroup I.
Treatments for Group III consisted of: (a)injectionis ofprogesterone equivalent
to and concurrent with those administered to Group I ; and b(C) control intuba-
tions of 01 ml. of the solvent Tween-60, concurrent with " b " for Group I.
'I'reatments for Grroup IV consisted of both a(C) and b(C) as described above.
Group V was subdivided into three smaller groups: V-a(C), V-b(C), and
V-O(C); each subgroup received, respectively, treatment a(C) only, b(C) only,
and O(C) no treatment. All mice were kept under observation until they were
moribund or were found dead. Except in a few cases where animals were lost
because ofcannibalism or autolysis all were examined for grosspathologic changes:
tissues showing pathologic changes were fixed in Bouin's solution and studied
histologically after staining with H. and E. This report is limited to the neo-
plastic results obtained during the first 27 weeks of the experiment (for reasons
given in paragraph two under " Results ").
RESULTS
As slhowniin Table I, the most impressive grossobservationi was the development
of mammary tumors in Group I, treated concurrently with progesterone and MCA.
The acceleration of tumor genesis and growth in this group was striking, since all
effectively exposed survivors (23 '25) had multiple large primary tumors before the
first tumor was detected in any other group (Group I cf. II, Table I). Administra-
tion of MCA to Group I was stopped after 22 weeks, when it was apparent that a
tumor incidence of 10000 had been achieved; by contrast, carcinogenic intubations
ofMCA were continued in Group II for 35 weeks, at which time all exposures were
terminated without a comparable tumor incidence in any other group.
Injections of progesterone ("a") and peanut oil (" a-C ") were stopped in all
groups after 19 weeks, when accumulated oil pockets in the regions ofthe right and
left inguinal lymph nodes made further injections in those sites impractical. In
view of the depletion of progesterone from the oil pockets, and its systemic
evanescence, the gross observations on incidence and time for tumor appearance
here reported are limited to those obtained through the 8th week after progesterone
administration was terminated (the 27th week of the experiment). During that
period, the development of mammary tumors in two progesterone treated mice in
Group III, in comparison with the total absence of tumors in control Groups IN"
and V, suggested the possibility that the progestational state induced in Group III
may have enhanced viral carcinogenesis in those animals. Obviously, more data
are needed on this aspect.
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The tumors elicited in Group III were typically adenocarcinomas of a basic
acinar structure classified according to Dunn (1959) as Type A mammary tumors,
-ith areas of cystic, papillary, glandular, and aggregated cell cords, bands, and
nest variants listed according to her system as Type B tumors. Both Types A
and B have been reported remarkably frequent in mice with the MTA (Dunn, 1959).
By contrast, those elicited in Groups I and II comprised a wide spectrum of types
and variants (Table I, column 6), many of them previously reported to have been
induced in mice presumable free of the viral agent, that were treated with MCA
(Andervont and Dunn, 1953). The effects of progesterone were therefore associa-
ted with a profoundly more rapid development and a higher incidence of mam-
mary tumors, but with no change in the histological appearance of the tumors
observed in its absence.
DISCUSSION
The term "co-carcinogen " originated by Shear in 1938, was meant to desig-
nate a class of agents not carcinogenic per se, which enhanced the effect of a
carcinogen, especially when the carcinogen was weak or administered under con-
ditions otherwise inadequate for tumor development (Shear, 1938). Later studies
demonstrated that most if not all substances designated as " co-carcinogens " or
" promoters " were either tumor-inducing agents that were tested under conditions
which, at first, did not disclose their full carcinogenic potential (i.e., croton oil,
urethane), or solvent agents that increased the solubility and penetrability of
residual carcinogens applied to the skin of mice (i.e., Tween-60), or crude solvents,
totally inactive for tumor genesis, that were contaminated with trace amounts of
laboratory or industrial carcinogens (i.e., phenol, or the basic oil fraction of high
temperature coal tar or creosote oil (Poel, 1956, 1963). Since an adequate
definition for a hypothetical substance was thus created which persisted in the
literature, and since neither in this nor any study published to date is there con-
clusive evidence that progesterone perse is carcinogenic, progesterone, tentatively,
might be considered a co-carcinogen for mammary carcinogenesis; possibly the
first co-carcinogen to fit the definition proposed by Shear.
A review of the literature discloses seemingly contrasting reports dealing with
the biologic effects of exogenous progesterone in mammary tumor genesis, the
effects of progesterone plus estrogen as compared with progesterone administered
alone, and the effects of pregnancy, pseudo-pregnancy and progesterone as com-
pared with synthetic progestins on mammary tumor growth. Heiman (1943,
1945) found that progesterone, injected subcutaneously, reduced the incidence of
mammary tumors in mice and inhibited the growth of mammary fibroadenomas
in female rats. On the other hand, Cantarow and co-workers (1948) were the first
to demonstrate that progesterone enhanced mammary tumor genesis in rats fed
the carcinogen precursor, 2-acetylaminofluorene. Huggins and co-workers (1959)
confirmed the enhancing effect of progesterone on mammary tumor growth by
demonstrating a similar phenomenon in rats fed the topical carcinogen, MCA,
while Dao and Sunderland (1959) described acceleration in the growth of MCA-
induced mammary tumors in rats treated with progesterone, as well as in preg-
nancy and pseudo-pregnancy, when levels ofendogenous progesterone and estrogen
are elevated. Jull (1954) found that the combination of progesterone plus
estrogen treatment significantly increased the incidence of mammary cancer in
ovariectomized mice subjected to MCA by skin application. The observations of
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Sydnor and Cockrell (196:3) also indicate an accelerating influence on mammary
tumor induction of progesterone and estrogen combined, injected subcutaneously
inito ovariectomized. MICA-fed rats. By contrast, the studies in Huggins's
laboratory (Huggins. Moon and MIorii, 1962) showed a decreased incidence of
mammary (ancer and a longer induction period, in dimethylbenzanthracene-fed
intact rats treated with progesterone and estradiol-17fi. Whether the co-carcino-
genic effects ofexogenous progesterone differ from those of the synthetic progestins
currently available for human contraceptive purposes is yet to be established.
(ruenstein, Shay and Shimkin (1964) reported that the synthetic progestin,
Norethynodrel, (in " Enovid ") neither enhanced nor retarded mammary car-
einogenesis evoked in rats by gastric intubations of MCA, and that progesterone
didnotincrease the incidence ofmammary tumors, although their mean appearance
time may have been shortened. Preliminary studies in our laboratory with two
commercially available oral contraceptives (for the human) showed each to be
inieffective for maintaining an anovulatory state when fed to mice at dose levels up
to 25 times that effective in the human female: they were equally ineffective in
altering mammary tumor induction in those animals.
The divergence in reported findings may be more apparent than real, in view of
differences in experimental test animals, agents. and test conditions. They do not
inecessarily represent conflicting observations: they do represent the need for
further investigations to clarifv our present limited understanding of hormone-
carcinogenesis relationships. Laboratory results to resolve these and related
questions with experimental animals should be available long before adequate
epidemiologic studies give definitive answers pertinent to man. Although narrow
limits must be imposed on the interpretation of laboratory data, and those should
not be extrapolated directly to man, such data may suggest a parallel hazard for
the humain which may require decades to evolve. In that sense, the observations
now reported for at least one experimental animal system suggest, in part, greater
caution than has been demonstrated to date in the indiscriminate human con-
sumption of newer oral contraceptives and synthetic progestins. and the need for
clinico-epidemiologic explorations for a possible human parallel to those seen
experimentallv.
SUMMARY
Progesteronie was found to be a potent co-carcinogen for the induction and
dlevelopment of mammary tumors. when administered for the purpose of main-
taining an anovulatory state in methylcholanthrene-fed C'3H virgin female mice.
In light of this observation, the absence of epidemiologic data pertinent to the
long-term effects of the prolonged anovulatory state, especially in women pre-
disposed to the development of mammary tumors. suggests:
(a) The ineed for (linico-epidemiologic studies to ascertain a possible
lhumani parallel
(b) greater cautioni thain has been demonstrated to date in the uitiliza-
tioni of progestins as oral contraceptive agents.
The author is indebted to Dolores Stanton, Mlary Harris. Arthur Carter. Jaine
Pool, and Bobby Kilgore for their devoted service in this study.
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